NVAX financials
Novavax (NVAX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
NVAX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $1.12B | $1.05B | $563.27M | $440.30M | 2.54 |
| 2024 | $682.16M | $479.42M | -$248.93M | -$187.50M | -1.23 |
| 2023 | $556.38M | $212.61M | -$566.51M | -$545.06M | -5.41 |
| 2022 | $1.60B | $696.31M | -$644.74M | -$657.94M | -8.42 |
| 2021 | $197.58M | $197.58M | -$1.69B | -$1.74B | -23.44 |
| 2020 | $22.39M | $22.39M | -$416.72M | -$418.26M | -7.43 |
- NVAX revenue was $1.12B in fiscal 2025, net income $440.30M.
Updated 2026-11-02 23:14 UTC